Immunomodulatory effect of the purine nucleoside inosine following spinal cord contusion injury in rat
Immunomodulatory effect of the purine nucleoside inosine following spinal cord contusion injury in rat
复制标题
DOI：
10.1038/sj.sc.3102057
复制
发表时间：
2008-01-01
期刊：
影响因子：
2.2
通讯作者：
Stelzner, D. J.
中科院分区：
文献类型：
--
作者：
Conta, A. C.;Stelzner, D. J.
研究设计：使用成年大鼠中度脊髓挫伤（SCI）模型进行体内研究。目的：评估嘌呤核苷肌苷对病变部位及其附近以及远离损伤中心的白质区域的巨噬细胞/小胶质细胞活化的免疫调节作用。地点：美国纽约州锡拉丘兹纽约州立大学上州医科大学细胞与发育生物学系。方法：动物（N = 56）受伤在 T9-T10 脊髓水平使用中度 SCI，并根据治疗模式分为三组。大鼠接受腹膜内或皮下注射肌苷 (N 28) 或载体 (N 28)。对脊髓组织进行 ED-1 免疫反应性处理，并使用 Cavalieri 方法和无偏立体学计算 ED-1(+) 轮廓的体积分数。结果：与载体对照相比，仅在每天两次、为期 6 周的治疗过程后，病变部位及其周围的灰色和侧向白质区域内 ED-1(+) 轮廓的体积分数显着降低，并且远离病变的白质区域不受所有肌苷治疗的影响结论：在 SCI 后 15 分钟开始持续皮下注射肌苷并持续整个 6 周的生存期，在病变部位及其周围发挥了免疫调节作用。
Study design: In vivo study using a moderate spinal cord contusion injury (SCI) model in adult rat.Objective: To assess the immunomodulatory effects of the purine nucleoside inosine on macrophage/microglia activation at and near the lesion site and in white matter areas remote from the injury epicenter.Setting: Department of Cell and Developmental Biology, SUNY Upstate Medical University, Syracuse, NY, USA.Methods: Animals (N = 56) were injured using a moderate SCI at T9-T10 spinal level and were divided into three groups, depending on treatment paradigm. Rats received either intraperitoneal or subcutaneous injections of inosine ( N 28) or vehicle ( N 28). Spinal cord tissue was processed for ED-1 immunoreactivity and the volume fraction of ED-1(+) profiles was calculated using the Cavalieri method and unbiased stereology.Results: The volume fraction of ED-1(+) profiles within gray and lateral white matter regions at and around the lesion site was significantly reduced only following a twice daily-6 week treatment course, compared with vehicle controls, and white matter areas remote from the lesion were unaffected by all inosine treatment paradigms.Conclusions: Continued subcutaneous delivery of inosine, beginning 15-min post-SCI and persisting throughout the survival period of 6 weeks exerted immunomodulatory effects at and around the lesion site.